Academics
follow us
  • Linkedin
  • Twitter
  • Facebook
  • Youtube
  • Instagram
Feedback
Patent Number:- IN450418

Hydrazide Based HDAC3 Selective Inhibitors

  • Sector: Pharmaceutical Technology,
  • IPC: C07D,
 

Need

Existing embodiments may limit the scope of inventive applications, suggesting a need for further innovation in histone deacetylase 3 inhibitors.

Solution

The invention provides potent, selective HDAC3 inhibitors with a novel benzoylhydrazide scaffold and a simplified synthesis process, enhancing drug development efficiency

Innovation

This invention introduces a compound selectively inhibiting HDAC enzymes, with a unique structure for enhanced HDAC3 specificity and a streamlined synthesis, offering significant advancements in therapeutic applications and manufacturing efficiency.

Market Analysis

Market: Pharmaceutical industry, particularly in cancer therapeutics

CAGR: Around 7-10% (based on the latest trends in the pharmaceutical industry)

Potential Indian Clients: Pharmaceutical companies involved in cancer research and drug development, research institutions focusing on cancer therapeutics

Why Invest?


Epigenetic

Selective Inhibitors

Genetic expression

Benzoylhydrazide

At a Glance


Current TRL: NA

Funded by: NA

IPC: C07D

Domain: Chemistry, Pharmaceutical Sciences

For more information, reach out to Mr. Rajneesh Kumar, Head of the Technology Transfer Office, at tto@bits-pilani.ac.in and 01596-255515.